Old National Again Named Among the 50 Most Community-Minded U.S. Companies by Points of Light
The Civic 50
EVANSVILLE, Ind., June 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ONB) – For the second consecutive year, Old National Bancorp ('Old National') has been named by Points of Light as one of 'The Civic 50' honorees for 2025. This annual designation is reserved for the 50 most community-minded companies in the nation.
A global nonprofit that inspires, equips and mobilizes people to take action that changes the world, Points of Light has recognized the 50 most community-minded companies in the nation every year since 2012. The Civic 50 award is based on employee volunteering, community investment, corporate citizenship and social impact programs.
'Our team members love rolling up their sleeves and making a difference in their communities, as evidenced by the more than 67,000 collective volunteer hours they logged in 2024,' said Jim Ryan, Old National Chairman and CEO. 'Old National is honored to again be recognized by Points of Light as an organization that truly puts our values into action.'
Combined, The Civic 50 companies for 2025 have engaged more than 460,000 employees to volunteer more than 6.5 million hours in their communities. That's double the average for U.S. companies not in The Civic 50.
'In an ever-evolving landscape, companies are looking to ensure that they can meet the needs of their communities, customers, and stakeholders,' said Jennifer Sirangelo, President and CEO, Points of Light. 'Companies like Old National are leading the way in showing how social impact benefits their employee's well-being, strengthens the communities where they do business, and brings value and meaning to their work. Their efforts provide a model for others looking to bring the benefits of volunteering and social impact to their workforce, and they're extremely deserving of this recognition.'
The Civic 50 honorees are companies with annual U.S. revenues of at least $1 billion. They are selected based on four dimensions of their corporate citizenship and social impact programs:
Investment of resources and volunteerism
Integration across business functions
Institutionalization through policies and systems
Impact measurement
You can click here for the full list of The Civic 50 honorees. Additionally, for more information and to view Old National's latest Community Action Report, click here.
ABOUT OLD NATIONALOld National Bancorp (NASDAQ: ONB) is the holding company of Old National Bank. As the fifth largest commercial bank headquartered in the Midwest, Old National proudly serves clients primarily in the Midwest and Southeast. With approximately $70 billion of assets and $37 billion of assets under management (including Bremer Financial Corporation on a pro forma basis as of March 31, 2025), Old National ranks among the top 25 banking companies headquartered in the United States. Tracing our roots to 1834, Old National focuses on building long-term, highly valued partnerships with clients while also strengthening and supporting the communities we serve. In addition to providing extensive services in consumer and commercial banking, Old National offers comprehensive wealth management and capital markets services. For more information and financial data, please visit Investor Relations at oldnational.com. In 2025, Points of Light again named Old National as one of "The Civic 50" -- an honor reserved for the 50 most community-minded companies in the United States.
ABOUT POINTS OF LIGHTPoints of Light is a nonpartisan, global nonprofit organization that inspires, equips, and mobilizes millions of people to create positive change through volunteering and civic engagement. Through work with nonprofits, companies and social impact leaders, the organization galvanizes volunteers to meet critical needs in communities. As the world's largest organization dedicated to increasing volunteer service, Points of Light engages more than 3.8 million volunteers across 32 countries. For more information, visit pointsoflight.org.
Investor Relations:Lynell Durchholz(812) 464-1366lynell.durchholz@oldnational.com
Media Relations:Rick Vach(904) 535-9489rick.vach@oldnational.com
An image accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8ef16551-151e-4885-a99d-ec031f84e1feSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Meydan Free Zone Leads Compliance Innovation with Smooth Digital Setup Model
Meydan Free Zone launches a fully digital compliance system aligned with UAE and global standards, offering fast approvals, real-time tracking, and risk-based profiling to help entrepreneurs stay audit-ready, meet regulatory demands, and grow efficiently in one of the world's most scrutinized business Courtesy of Meydan Free Zone DUBAI, United Arab Emirates, June 12, 2025 (GLOBE NEWSWIRE) -- In a city recognized for e-government innovation, Meydan Free Zone is setting a new benchmark for digital business formation, unveiling a fully online setup experience that puts trust and transparency at the core of every step. Responding to the rising demand for regulatory accuracy, speed, and clarity, Meydan Free Zone has engineered a five-step, technology-enabled setup process. The system eliminates delays and errors, equipping founders with the tools and confidence needed to scale in one of the world's fastest-moving markets. 'Founders don't just want to move fast—they want to be trusted by banks, regulators, and partners from day one,' said Mohammad Bin Humaidan Al Falasi, Director of Free Zone Licensing at Meydan Free Zone. 'Our platform delivers that trust through technology, automation, and compliance built into every step.' A Fully Digital, Error-Free Setup Journey The Meydan Free Zone experience begins with guided business activity selection, ensuring each company aligns with UAE licensing and banking standards. Entrepreneurs receive legal structure and naming support, and built-in screening protocols prevent delays caused by inconsistencies or regulatory red flags. All submitted documents are subjected to compliance-grade checks, with digital workflows verifying the source of wealth, shareholder structures, and KYC data in accordance with FATF and UAE regulations. Once approvals are secured, trade licenses can be issued in as little as 60 minutes. A key advantage is Meydan's support for corporate bank account opening—a common challenge for new businesses. The platform provides banks with World Check screenings, verified KYC data, and clear shareholder structures, ensuring high approval rates and minimizing delays due to missing or misaligned information. Technology-Driven Transparency and Regulatory Alignment Meydan Free Zone integrates directly with Dubai's Live Compliance Dashboard, enabling real-time document validation and regulatory tracking. The entire setup process is remote, using e-signatures, AI chat assistance, and a blockchain-secured portal to provide full transparency and data integrity. The platform's enhanced compliance engine, launched earlier this year, automates source-of-funds verification, risk profiling, and ongoing due diligence, all aligned with UAE Federal Law and FATF standards. This ensures every business is prepared to meet the city's rigorous regulatory expectations from day one. Recognized as a qualified free zone under the UAE corporate tax framework, Meydan Free Zone offers eligible businesses 0% corporate tax on qualifying income, with registration and filing requirements smoothly integrated into the setup journey. With over 33,000 regulatory inspections conducted in Q1 2023 across the UAE, staying compliant from inception is essential. Meydan's structured digital workflow eliminates setup errors, streamlines government approvals, and ensures that all regulatory documents are aligned with bank and partner requirements, providing entrepreneurs with a clear, easy path from concept to operational launch. Setting the Gold Standard for Modern Business Formation Meydan Free Zone's dedication to a simple, secure, and fully digital setup positions it as a cornerstone of Dubai's future-forward business environment. The platform features UAE Pass connection, ISO-certified data protection, guaranteed bank account access, and real-time regulatory alignment.. About Meydan Free Zone Meydan Free Zone is one of Dubai's most future-focused business hubs. It offers a fully digital setup experience, comprehensive compliance support, and access to over 2,500 business activities. Built for speed, transparency, and simplicity, Meydan empowers entrepreneurs to scale confidently from Dubai to the world. Contact Information: Contact Person's Name: Anisha SagarOrganization / Company: Meydan Free ZoneCompany website: Email Address: anisha@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Encore Data Products Attending and Exhibiting at ISTE 2025: Showcasing Next-Gen Educational Tech
Lafayette, June 12, 2025 (GLOBE NEWSWIRE) -- Lafayette, Colorado - Encore Data Products is set to showcase its latest educational technology at the ISTE 2025 conference, happening from June 29 to July 2 in San Antonio. This event is a chance for Encore Data Products to connect with educators and industry experts, showing their dedication to improving learning experiences through cutting-edge tech solutions. One of the most exciting announcements this year is Encore Data Products' expansion into the Translation and Interpretation category with the introduction of IRIS Pen scanners, a powerful tool that helps break language barriers in the classroom and supports diverse learning needs. These smart pens instantly scan and translate printed text into multiple languages, making them ideal for multilingual students, ESL learners, and educators alike. The company is well-known for its wide range of products that serve schools, libraries, and businesses. They offer high-quality headphones, AV technology, and clean & healthy supplies, emphasizing their mission to provide dependable and innovative educational tools. At the conference, visitors will be able to check out their interactive learning tools, such as headphones with microphones and document cameras. They will also introduce some new portable and protective gear. A representative from Encore Data Products, shared her excitement by saying, "The ISTE conference is a fantastic platform for us to connect with educators and tech enthusiasts, demonstrating how our solutions can transform learning environments." She expressed their eagerness to interact with educators from all over and show how their customizable solutions can help make education more interactive and inclusive. The ISTE 2025 conference will feature many exhibitors, and Encore Data Products plans to use this opportunity to highlight their advanced AV technology. They will showcase products like charge & sync solutions and touch-enabled displays, focusing on how versatile and durable their technology is for classrooms. This is part of their strategy to smoothly incorporate digital tools into educational programs, offering practical and efficient resources to teachers and students. To explore the complete range of AV technology offered by Encore Data Products, including charge & sync solutions, visit the AV technology section on their website. A key aspect of Encore Data Products' display will be their emphasis on clean and healthy supplies. Recognizing the importance of hygiene, especially after global health challenges, the company offers solutions like electronic sanitizers and disposable headphone covers for safe shared spaces. These offerings are a response to modern educational needs, ensuring technology doesn't compromise the health of students and staff. Moreover, Encore Data Products will present their STEAM and STEM products, which are meant to support hands-on learning in science, technology, engineering, arts, and mathematics. Their products are designed to encourage teamwork and creative problem-solving. "Participating in ISTE allows us to align our innovations with the current trends and needs identified by educators," added a representative. "Our dedication to supporting educational environments through tailored solutions continues to drive our exploration of new technologies and practices." Encore Data Products is committed to promoting educational excellence, using this conference as a platform to showcase their current products such as the scanner and reading pen, and also learn from educators. This engagement helps shape future product development, reinforcing their reputation as a reliable partner in educational technology. For detailed information about their wide range of headphones and AV accessories, visit the headphones and AV accessories sections on their website. Their presence at ISTE 2025 is intended to deepen conversations about education technology's role in today's classrooms. Attendees looking to explore effective educational tools and gain insights into future-ready learning environments will find value in Encore Data Products' exhibit. The ISTE conference is known for bringing together educators and tech leaders to discuss the future of educational technology. By attending this year, Encore Data Products aims to contribute meaningfully to these discussions with practical solutions that meet the ever-changing needs of educators. The company's exhibit will be open throughout the conference from June 29 to July 2, offering hands-on demonstrations and expert consultations for all attendees. Recent News: Encore Data Products Unveils Califone Soft Floor Rockers and Gaming Chairs for Ultimate Comfort and Support ### For more information about Encore Data Products, contact the company here:Encore Data ProductsMedia Relations866-926-1669marketing@ Majestic Drive, Suite 5Lafayette, Colorado 80026 CONTACT: Media RelationsSign in to access your portfolio
Yahoo
34 minutes ago
- Yahoo
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis -- CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®/AYVAKYT® (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. "Our presentations feature large patient populations from the PIONEER, PATHFINDER and EXPLORER trials, with follow-up reaching up to five years in ISM and up to 6.5 years in advanced SM, reflecting both the favorable long-term benefits of AYVAKIT and the unprecedented datasets we have amassed over time," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "AYVAKIT has shown transformative clinical outcomes for patients across the spectrum of SM, including sustained disease control in ISM and prolonged survival in advanced SM. These compelling results have translated into real-world practice, with clinicians expanding their view of who is an appropriate candidate for disease-modifying therapy after positive AYVAKIT experiences, and treatment durations trending toward multiple years." PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM As previously presented,1 AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3 percent) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. This data presentation follows the May 2025 online publication of PIONEER two-year efficacy and safety data in The Journal of Allergy and Clinical Immunology: In Practice. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells. Data Presentations EHA2025 Congress Oral Presentation: The Revised Mutation-Adjusted Risk Score (MARS-R) for Predicting Overall Survival in Patients with Advanced Systemic Mastocytosis Treated with Midostaurin or Avapritinib (Abstract S216) Poster Presentation: Blood-Based Proteomics for Deeper Insights Into Indolent Systemic Mastocytosis: The PIONEER Trial Experience (Abstract PS1838) Poster Presentation: High Accuracy of Peripheral Blood Testing Using Machine Learning–Derived Predictive Models to Distinguish Advanced from Indolent Systemic Mastocytosis: Analysis of Avapritinib and Elenestinib Trial Data (Abstract PF1310) Publication-Only Abstract: Phase 2/3 HARBOR Study of Elenestinib in ISM: A Trial-in-Progress Update of Novel Endpoints and Biomarkers Aimed at Evaluating Disease Modification (Abstract PB3108) EAACI Congress 2025 Flash Talk Presentation: Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study (Abstract 000621) Flash Talk Presentation: The Socio-Emotional Impact of Indolent Systemic Mastocytosis: Insights from the PRISM Survey (Abstract 000488) Poster Presentation: The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients with Indolent Systemic Mastocytosis (Abstract 001121) Data presentations are being made available in the "Science―Publications and Presentations" section of the company's website at About Systemic Mastocytosis Systemic mastocytosis (SM) is a rare disease driven by the KIT D816V mutation in about 95 percent of cases. Uncontrolled proliferation and activation of mast cells result in chronic, severe and often unpredictable symptoms across multiple organ systems. The vast majority of those affected have indolent systemic mastocytosis (ISM). A broad range of symptoms, including anaphylaxis, maculopapular rash, pruritus, diarrhea, brain fog, fatigue and bone pain, frequently persist in patients with ISM despite treatment with multiple symptom-directed therapies. This burden of disease can lead to a profound, negative impact on quality of life. Patients often live in fear of severe, unexpected symptoms, have limited ability to work or perform daily activities, and isolate themselves to protect against unpredictable triggers. Until 2023, there were no approved therapies for the treatment of ISM. A minority of patients have advanced SM, which encompasses a group of high-risk SM subtypes including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL). In addition to mast cell activation symptoms, advanced SM is associated with organ damage due to mast cell infiltration and poor survival. About AYVAKIT AYVAKIT (avapritinib) is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) to treat the root cause of SM. It was FDA approved for the treatment of advanced SM in June 2021 and ISM in May 2023. It now is indicated in adults with ISM, adults with advanced SM, including ASM, SM-AHN and MCL, and adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. The medicine is approved in the EU as AYVAKYT for the treatment of adults with ISM with moderate to severe symptoms inadequately controlled on symptomatic treatment, adults with ASM, SM-AHN or MCL, after at least one systemic therapy, and adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation. The therapy is not recommended for the treatment of patients with low platelet counts (less than 50,000/µL). Globally, the medicine is approved for one or more indications in 16 countries, including China where it is marketed by CStone Pharmaceuticals, paying tiered percentage royalties on sales. Please click here to see the full U.S. Prescribing Information for AYVAKIT, and click here to see the European Summary of Product Characteristics for AYVAKYT. Important Safety Information Intracranial Hemorrhage — Serious intracranial hemorrhage (ICH) may occur with AYVAKIT treatment; fatal events occurred in <1% of patients. Overall, ICH (eg, subdural hematoma, ICH, and cerebral hemorrhage) occurred in 2.9% of 749 patients who received AYVAKIT in clinical trials. In Advanced SM patients who received AYVAKIT at 200 mg daily, ICH occurred in 2 of 75 patients (2.7%) who had platelet counts ≥50 x 109/L prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts. In ISM patients, no events of ICH occurred in the 246 patients who received any dose of AYVAKIT in the PIONEER study. Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of ICH. Permanently discontinue AYVAKIT if ICH of any grade occurs. In Advanced SM patients, a platelet count must be performed prior to initiating therapy. AYVAKIT is not recommended in Advanced SM patients with platelet counts <50 x 109/L. Following treatment initiation, platelet counts must be performed every 2 weeks for the first 8 weeks. After 8 weeks of treatment, monitor platelet counts every 2 weeks or as clinically indicated based on platelet counts. Manage platelet counts of <50 x 109/L by treatment interruption or dose reduction. Cognitive Effects — Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 33% of 995 patients overall in patients who received AYVAKIT in clinical trials including: 28% of 148 Advanced SM patients (3% were Grade ≥3), and 7.8% of patients with ISM who received AYVAKIT + best supportive care (BSC) versus 7.0% of patients who received placebo + BSC (<1% were Grade 3). Depending on the severity and indication, withhold AYVAKIT and then resume at same dose or at a reduced dose upon improvement, or permanently discontinue. Photosensitivity — AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment. Embryo-Fetal Toxicity — AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective method of contraception during treatment with AYVAKIT and for 6 weeks after the final dose of AYVAKIT. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks after the final dose. Adverse Reactions — The most common adverse reactions (≥20%) in patients with Advanced SM were edema, diarrhea, nausea, and fatigue/asthenia. The most common adverse reactions (≥10%) in patients with ISM were eye edema, dizziness, peripheral edema, and flushing. Drug Interactions — Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors. If coadministration with a moderate CYP3A inhibitor cannot be avoided in patients with Advanced SM, reduce dose of AYVAKIT. Avoid coadministration of AYVAKIT with strong or moderate CYP3A inducers. If contraception requires estrogen, limit ethinyl estradiol to ≤20 mcg unless a higher dose is necessary. To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or AYVAKIT is available in 25-mg, 50-mg, 100-mg and 200-mg tablets. Please click here to see the full U.S. Prescribing Information for AYVAKIT. About Blueprint Medicines Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with SM in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases and solid tumors. For more information, visit and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Blueprint Medicines' leadership role and its ability to transform treatment across the spectrum of SM, including sustained disease control in ISM and prolonged survival in advanced SM; AYVAKIT/AYVAKYT's position as the durable standard of care and clinicians' view of appropriate candidates and treatment duration; plans and expectations for Blueprint Medicines' current or future approved drugs and drug candidates; the potential benefits of any of Blueprint Medicines' current or future approved drugs or drug candidates in treating patients; and Blueprint Medicines' strategy, goals, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to Blueprint Medicines' ability and plans in continuing to build out and expand a commercial infrastructure, and successfully launching, marketing and selling current or future approved products; Blueprint Medicines' ability to successfully expand the approved indications for AYVAKIT/AYVAKYT or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines' drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for AYVAKIT/AYVAKYT or any drug candidates it is developing; Blueprint Medicines' ability to successfully expand its operations, research platform and portfolio of therapeutic candidates, and the timing and costs thereof; the success of Blueprint Medicines' current and future collaborations, financing arrangements, partnerships or licensing arrangements; and the ability of the parties to consummate the proposed merger between Blueprint Medicines and Sanofi on the timeline anticipated or at all, including the occurrence of any event, change or other circumstance that could give rise to the termination of the merger. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements. Footnote 1 Reported at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress Trademarks Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation. View original content to download multimedia: SOURCE Blueprint Medicines Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
